Current Report Filing (8-k)
January 10 2023 - 08:05AM
Edgar (US Regulatory)
Inogen
Incfalse000129413300012941332023-01-102023-01-10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
|
Date of Report (Date of earliest event reported):
January 10, 2023
|
INOGEN, INC.
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
Delaware
|
001-36309
|
33-0989359
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission File Number)
|
(IRS Employer
Identification No.)
|
|
|
|
|
|
301 Coromar Drive
|
|
Goleta,
California
|
|
93117
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
|
Registrant’s Telephone Number, Including Area Code:
(805)
562-0500
|
(Former Name or Former Address, if Changed Since Last
Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the
Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock, $0.001 par value
|
|
INGN
|
|
The NASDAQ Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§ 230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On January 10, 2023, Inogen, Inc. (the “Company”) issued a press
release reporting preliminary, unaudited revenue results for the
fourth quarter and full year ended December 31, 2022. The amounts
included in the press release are preliminary, have not been
audited and are subject to change upon completion of the Company’s
audited financial statements for the year ended December 31, 2022.
Additional information and disclosures would be required for a more
complete understanding of the Company’s financial position and
results of operations as of December 31, 2022. A copy of the press
release is furnished herewith as Exhibit 99.1 to this Current
Report 8-K.
Item 7.01. Regulation FD Disclosure.
Investor Conference
The chief executive officer and chief financial officer of the
Company will participate in the 2023 J.P. Morgan Healthcare
Conference, which began on Monday, January 9, 2023. The chief
executive officer is scheduled to present at the conference on
Wednesday, January 11, 2023, at 10:30 a.m. Pacific Time. During the
conference and in separate sessions with analysts and investors,
the Company’s officers will refer to an updated slide presentation,
which the Company has posted to the Investor Relations page on the
Company’s website at www.inogen.com. Interested parties can access
the live audio webcast of this conference presentation from the
Events section of the Investor Relations page on the Company’s
website at www.inogen.com. The information posted on or that can be
accessed through Inogen’s website, including Inogen’s updated
corporate presentation, is not incorporated by reference herein,
and the inclusion of Inogen’s website address is an inactive
textual reference only.
The information furnished in this Current Report on Form 8-K under
Items 2.02 and 7.01 and the exhibit attached hereto, shall not be
deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise
subject to the liabilities of that section, nor shall it be deemed
incorporated by reference into any other filing under the
Securities Act of 1933, as amended or the Exchange Act, except as
expressly set forth by specific reference in such a
filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned thereunto duly authorized.
|
|
|
|
|
|
|
INOGEN, INC.
|
|
|
|
|
Date:
|
January 10, 2023
|
By:
|
/s/ Kristin Caltrider
|
|
|
|
Kristin Caltrider
Executive Vice President
Chief Financial Officer
Treasurer
(Principal Accounting and Financial Officer)
|
Inogen (NASDAQ:INGN)
Historical Stock Chart
From Apr 2023 to May 2023
Inogen (NASDAQ:INGN)
Historical Stock Chart
From May 2022 to May 2023